Can Tocilizumab Decrease Cartilage Oligomeric Matrix Protein Levels and Disease Activity in Patients with Long-Standing Rheumatoid Arthritis?

Objective: This study was designed is to determine the correlation between serum calcium level and serum cartilage oligomeric matrix protein (COMP) level in Indonesian patients with rheumatoid arthritis (RA).Subjects and Methods: The subjects are patients who visit the rheumatology clinic at a government hospital in Bandung, Indonesia. Serum calcium level was determined by a complexometric method, and the serum COMP level was determined by enzyme-linked immunosorbent assay. Statistical analysis was performed with R software.Results: The serum calcium level was 82.24±44.82 mg/mL in RA patients and 99.04±60.56 mg/mL in normal controls. The serum COMP level was 843.80±35.79 ng/ml in RA patients and 830.00±48.92 ng/ml in normal controls.Conclusion: There is no correlation between serum calcium level and serum COMP levels in RA patients (p=0.967 and rho=0.006).

Download Full-text

Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis

Zeitschrift für Rheumatologie ◽

10.1007/s00393-015-1647-5 ◽

2015 ◽

Vol 75 (9) ◽

pp. 917-923 ◽

Cited By ~ 17

Author(s):

A.O. El Defrawy ◽

T.A. Gheita ◽

H.M. Raslan ◽

M.M. El Ansary ◽

A.H. El Awar

Keyword(s):

Rheumatoid Arthritis ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

Established Rheumatoid Arthritis ◽

Protein Levels

Download Full-text

Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis

The Journal of Rheumatology ◽

10.3899/jrheum.101241 ◽

2011 ◽

Vol 38 (8) ◽

pp. 1563-1568 ◽

Cited By ~ 12

Author(s):

ANNE F. CHRISTENSEN ◽

HANNE LINDEGAARD ◽

KIM HØRSLEV-PETERSEN ◽

MERETE L. HETLAND ◽

BO EJBJERG ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

Health Assessment ◽

Disease Process ◽

Suppressive Effect ◽

Cyclic Citrullinated Peptide ◽

Peptide Antibody ◽

Citrullinated Peptide

Objective.Cyclic citrullinated peptide antibody (anti-CCP)-positive and anti-CCP-negative rheumatoid arthritis (RA) have been suggested as 2 distinctive disease subsets with respect to disease activity and prognosis. Previously, we proposed that anti-CCP antibodies might have a chondrocyte-suppressive effect. We aimed to compare circulating cartilage oligomeric matrix protein (COMP), a marker of cartilage turnover, in untreated anti-CCP-positive and anti-CCP-negative RA, and to study the temporal pattern of COMP through 4 years of treatment, including the relationship to imaging and clinical findings.Methods.A total of 160 patients with newly diagnosed RA who were naive to disease-modifying antirheumatic drugs were included in the CIMESTRA trial. Ninety healthy blood donors served as controls. Demographic and disease measures including Disease Activity Score in 28 joints, IgM rheumatoid factor, anti-CCP, Health Assessment Questionnaire, visual analog scale scores for pain and global and physician assessment, and magnetic resonance imaging (MRI) of the nondominant hand were recorded at baseline. COMP in serum was measured by ELISA at inclusion and serially through 4 years.Results.Median baseline COMP was higher in patients with RA [9.8 U/l (interquartile range 8.96, 10.5)] compared with controls [8.3 U/l (IQR 7.84, 8.9); p < 0.001] and remained elevated at 4 years [10.8 U/l (IQR 10.2, 11.7); p < 0.001]. At baseline, anti-CCP-positive patients had lower COMP than anti-CCP-negative patients (p = 0.048). In anti-CCP-positive patients, COMP exhibited a parabolic course over 4 years, while COMP in anti-CCP-negative patients had an almost linear course. In anti-CCP-positive patients, COMP was associated with MRI edema and erosion score, while COMP was correlated with synovitis score in anti-CCP-negative individuals.Conclusion.Our study provides additional evidence for the existence of different disease pathways in anti-CCP-positive and anti-CCP-negative subsets of RA, and evidence that anti-CCP antibodies may be implicated in the disease process by modifying cartilage metabolism.

Download Full-text

Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity

Clinical Rheumatology ◽

10.1007/s10067-017-3817-0 ◽

2017 ◽

Vol 36 (12) ◽

pp. 2683-2688 ◽

Cited By ~ 7

Author(s):

Rajalingham Sakthiswary ◽

Shamala Rajalingam ◽

Heselynn Hussein ◽

Radhika Sridharan ◽

Abdul Wahab Asrul

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

Cartilage Thickness ◽

Knee Cartilage

Download Full-text

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

Arthritis Research & Therapy ◽

10.1186/s13075-021-02556-1 ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Marit Stockfelt ◽

Anna-Carin Lundell ◽

Merete Lund Hetland ◽

Mikkel Østergaard ◽

Till Uhlig ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trial ◽

Disease Activity ◽

Randomized Clinical Trial ◽

Early Rheumatoid Arthritis ◽

Treatment Initiation ◽

Certolizumab Pegol ◽

Type I ◽

Protein Levels ◽

Early Ra

Abstract Background The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect. Methods Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment. Results IFNα protein positivity was found in 26% of the patients, and of these, 92% were double-positive for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFNα protein levels were reduced 24 weeks after treatment initiation, and the absolute change was similar irrespective of treatment. IFNα protein positivity was associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization. Conclusion IFNα protein positivity is present in a subgroup of patients with early RA and associates with double-positivity for autoantibodies but not with disease activity. Pre-treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815.

Download Full-text

High specificity but low sensitivity of the cartilage oligomeric matrix protein (COMP) test in rheumatoid arthritis and osteoarthritis

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm.2010.081 ◽

2010 ◽

Vol 48 (4) ◽

Cited By ~ 3

Author(s):

Ana Lígia Bender ◽

Inês Guimaraes da Silveira ◽

Carlos Alberto von Mühlen ◽

Henrique Luiz Staub

Keyword(s):

Rheumatoid Arthritis ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

High Specificity ◽

Low Sensitivity

Download Full-text

CORRELATION STUDY OF DISEASE ACTIVITY SCORE AND SERUM CARTILAGE OLIGOMERIC MATRIX PROTEINLEVELS OF RHEUMATOID ARTHRITIS PATIENTS IN BANDUNG, INDONESIA

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2017.v10i1.15251 ◽

2016 ◽

Vol 10 (1) ◽

pp. 290

Author(s):

Nyi Mekar Saptarini ◽

Dainar Eka Pratiwi ◽

Ellin Febrina ◽

Marlia Singgih Wibowo ◽

Tutus Gusdinar

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Matrix Protein ◽

Disease Activity Score ◽

Correlation Study ◽

Activity Score ◽

Rheumatology Clinic ◽

Das 28 ◽

Moderate Disease ◽

Moderate Disease Activity

ABSTRACTObjective: This study was designed to determine the correlation between Disease Activity Score (DAS 28) and the serum Cartilage Oligomeric MatrixProtein (COMP) levels in Indonesian Rheumatoid Arthritis (RA) patients. Methods: The subjects were patients who visit the rheumatology clinic at one governmental hospital in Bandung, Indonesia. DAS was determinedby the QxMD Software based on erythrocyte sedimentation rate, and serum COMP levels were determined by enzyme-linked immunosorbent assay.Statistical analysis was conducted with IBM SPSS Statistics 23. Results: DAS 28 value was 3.36 ± 0.16 which indicates the moderate disease activity. Serum COMP levels were 843.80 ± 35.79 ng/ml in RA patientsand 830.00 ± 48.92 ng/ml in normal controls. Conclusion: There is no correlation between DAS 28 and serum COMP levels in RA patients (p = 0.496 and rho = 0.129). Keywords: Autoimmune disease, Rheumatoid arthritis monitoring, Cartilage oligomeric matrix protein, Disease activity score 28

Download Full-text

Rheumatoid Arthritis: Hyaluronic Acid and Cartilage Oligomeric Matrix Protein as Predictors of the Disease Progression

Biomedical & Pharmacology Journal ◽

10.13005/bpj/903 ◽

2016 ◽

Vol 9 (1) ◽

pp. 15-23

Author(s):

SAID AL-DALAEN ◽

AIMAN AL-QTAITAT ◽

MOHAMMAD AL-RAWASHDEH ◽

JIHAD ALZYOUD ◽

AIMAN AL-MAATHADI

Keyword(s):

Rheumatoid Arthritis ◽

Hyaluronic Acid ◽

Disease Progression ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

And Cartilage

Download Full-text

Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis

Biomarker Insights ◽

10.4137/bmi.s645 ◽

2009 ◽

Vol 4 ◽

pp. BMI.S645 ◽

Cited By ~ 53

Author(s):

Susan Tseng ◽

A. Hari Reddi ◽

Paul E. Di Cesare

Keyword(s):

Rheumatoid Arthritis ◽

Cartilage Oligomeric Matrix Protein ◽

Matrix Protein ◽

Clinical Manifestations ◽

Biological Marker ◽

Prognostic Indicator ◽

Cartilage Degradation ◽

Recent Onset ◽

Effect Of Treatment ◽

Early Phases

Arthritis is a chronic disease with a significant impact on the population. It damages the cartilage, synovium, and bone of the joints causing pain, impairment, and disability in patients. Current methods for diagnosis of and monitoring the disease are only able to detect clinical manifestations of arthritis late in the process. However, with the recent onset of successful treatments for rheumatoid arthritis and osteoarthritis, it becomes important to identify prognostic factors that can predict the evolution of arthritis. This is especially critical in the early phases of disease so that these treatments can be started as soon as possible to slow down progression of the disease. A valuable approach to monitor arthritis would be by measuring biological markers of cartilage degradation and repair to reflect variations in joint remodeling. One such potential biological marker of arthritis is cartilage oligomeric matrix protein (COMP). In various studies, COMP has shown promise as a diagnostic and prognostic indicator and as a marker of the disease severity and the effect of treatment. This review highlights the progress in the utilization of COMP as a biomarker of arthritis.

Download Full-text